Cimetidine pharmacokinetics in patients with Zollinger-Ellison syndrome
| Autor: | Katherine E. McArthur, Jean-Pierre Raufman, Ziemniak Ja, Jerry D. Gardner, Seaman Jj, Robert T. Jensen |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Adult
Male Metabolic Clearance Rate Drug Resistance Pharmacology Intestinal absorption Gastric Acid Zollinger-Ellison Syndrome chemistry.chemical_compound Pharmacokinetics Humans Medicine Cimetidine Aged Parietal cell Hepatology business.industry Gastroenterology Middle Aged medicine.disease digestive system diseases Zollinger-Ellison syndrome Pentagastrin Kinetics medicine.anatomical_structure Intestinal Absorption chemistry Gastric acid Female business Histamine Half-Life medicine.drug |
| Zdroj: | Gastroenterology. 93:69-76 |
| ISSN: | 0016-5085 |
| DOI: | 10.1016/0016-5085(87)90316-7 |
| Popis: | Although most patients with Zollinger-Ellison syndrome can be effectively treated with histamine H2-receptor antagonists, many patients require large doses of drug to inhibit gastric acid secretion adequately. The purpose of the present study was to compare the pharmacokinetics of a 1200-mg oral dose of cimetidine in 9 patients with Zollinger-Ellison syndrome requiring more than 2.4 g/day of cimetidine with 5 age-matched normal volunteers receiving intravenous pentagastrin infusions. Poor responsiveness to cimetidine in patients with Zollinger-Ellison syndrome has several different causes. The concentration of cimetidine in the blood required to inhibit gastric acid secretion by 50% was markedly increased in 3 of the patients with Zollinger-Ellison syndrome, suggesting parietal cell resistance. One patient showed a substantial decrease in cimetidine absorption and 4 patients had delayed cimetidine absorption. Thus 7 of the 9 patients with Zollinger-Ellison syndrome who required more than 2.4 g/day of cimetidine to inhibit gastric acid secretion had abnormal cimetidine pharmacokinetics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|